Breast cancer is the most common cancer found in women in the United States, with an estimate of over 180,000 new cases every year. It is also the second leading cause of cancer deaths in women, after lung cancer, and is responsible for the deaths of over 40,000 women every year in the U.S.
1 The most common breast malignancy is invasive ductal carcinoma (IDC), which accounts for around 75 to 80% of invasive breast cancers, while invasive lobular carcinoma (ILC) accounts for most other invasive cases. As with all malignancies, early detection of breast cancer is the only way to effectively manage patients who suffer from this disease. According to the American Cancer Society (ACS),
2 the
survival rates for persons with breast cancer that are appropriately treated are as follows: 100% for stage 0, 100% for stage I, 92% for stage IIA, 81% for stage IIB, 67% for stage IIIA, 54% for stage IIIB, and 20% for stage IV. This indicates that improved diagnosis methods need to be developed to detect this cancer in its early stage when it is treatable and its survival rates are high.